CytoDyn announced that Max Lataillade, DO, MPH, has been appointed as Senior Vice President and Head of Clinical Development. Under his consulting agreement, Dr. Lataillade will lead the Company’s global research and development strategy and oversee end-to-end R&D activities to advance the Company’s clinical development pipeline. He most recently served as Vice President, Head of Early Development and Global Research Strategy at ViiV Healthcare.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYDY:
- CytoDyn engages Syneos Health as CRO for Phase II oncology trial
- CytoDyn announces preliminary findings in study with SMC Laboratories
- CytoDyn CEO says leronlimab has ‘potential to be life-changing therapeutic’
- CytoDyn engages CRO for Phase II inflammation trial
- CytoDyn completes FDA meeting on Phase II Study of leronlimab